On January 5, 2021 Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, reported that the Company’s management team will present and host meetings with investors and potential partners next week at the H.C. Wainwright BioConnect Conference, J.P. Morgan Healthcare Conference and 23rd Annual ICR Conference being held virtually between January 11-14, 2021 (Press release, Humanigen, JAN 5, 2021, View Source [SID1234573513]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will provide an update on enrollment for its Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19, an update on the commercial preparation ahead of a potential Emergency Use Authorization (EUA) for lenzilumab as well as an overview of the Company’s other programs.

Details for the upcoming virtual investor conferences are below:

H.C. Wainwright BioConnect Conference

Date: Monday, January 11, 2021
Presentation Viewable Starting at 6:00 AM ET
Event Link:
View Source

J.P. Morgan Healthcare Conference

Date: Wednesday, January 13, 2021
Presentation Time: 8:20 AM ET
Event Link:
View Source;kiosk=true

2021 ICR Conference

Date: Thursday, January 14, 2021
Fireside Chat with Cosme Ordonez, National Securities: 1:00 PM ET
Event Link:
https://icrinc.touchcast.com/showtime/icr-conference/embed/19b8209f-86ae-93a7-6351-107304d2f9d0